February 11, 2016
Updated results of the ELOQUENT-2 trial – a phase 3, randomized, open-label study – presented at the ASH Annual Meeting and Exposition focused on 3-year follow-up data. Results of the ELOQUENT-2 trial were one of several studies presented that focused on triple therapy combinations for multiple myeloma.
“Elotuzumab (Empliciti, Bristol-Myers Squibb) is a novel monoclonal antibody against this antigen known as [Signaling Lymphocytic Activation Molecule F7 (SLAMF7)],” said John Sweetenham, MD, chief medical editor of hematology for HemOnc Today and senior director of clinical affairs and executive medical director at Huntsman Cancer Institute at University of Utah. “This agent was added to other standard agents in a triple therapy combination and it produced very high response rates.”